Trial Profile
Mean Visual Acuity Changes Following Five Injections of Aflibercept and the Relationship Between Ocular and Serum Cytokine Levels and Mean Visual Acuity Gains in DME Patients
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 18 Mar 2024
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 11 Mar 2024 Planned End Date changed from 1 Jan 2024 to 1 Dec 2024.
- 11 Mar 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Sep 2024.
- 11 Mar 2024 Status changed from recruiting to active, no longer recruiting.